Study guide
4.2 Cardiovascular, Renal, and Endocrine Pharmacology
PEBC Pharmacist Evaluating Examination Exam
Track your progress as you read
Finished sections get a check mark.
1 Chapter 1: Introduction & The Canadian Pharmacy Practice Landscape
1.1 PEBC EE Blueprint, Format, Scoring, and IPG Certification Pathway 1.2 The Canadian Healthcare System, Canada Health Act, and Drug Regulation 1.3 Canadian Pharmacy Regulatory Framework, NAPRA Standards, and Professional Legislation
2 Chapter 2: Pharmaceutics & Drug Delivery Systems
2.1 Physicochemical Principles, Solubility, Ionization, and Stability 2.2 Solid Dosage Forms, Formulation Science, and Modified-Release Technologies 2.3 Liquid and Semisolid Dosage Forms, Dispersions, and Topical Delivery 2.4 Sterile Product Principles, Parenteral Delivery, and Biopharmaceuticals 2.5 Pharmaceutical Quality: GMP, Stability Testing, and Bioequivalence
3 Chapter 3: Biopharmaceutics & Clinical Pharmacokinetics
3.1 Drug Absorption, Distribution, Metabolism, and Elimination (ADME) 3.2 Bioavailability, Bioequivalence, and Biopharmaceutics Classification System (BCS) 3.3 Pharmacokinetic Modeling, Parameters, and Dosing Calculations 3.4 Therapeutic Drug Monitoring (TDM) and Clinical Application
4 Chapter 4: Pharmacology, Toxicology & Pharmacogenetics
4.1 Autonomic and Central Nervous System Pharmacology 4.2 Cardiovascular, Renal, and Endocrine Pharmacology 4.3 Clinical Toxicology, Overdose Management, and Antidotes 4.4 Biologics, Biosimilars, and Pharmacogenetics
5 Chapter 5: Pathophysiology & Clinical Assessment
5.1 Clinical Laboratory Diagnostics, Biomarkers, and Vital Signs 5.2 Cardiovascular and Respiratory Pathophysiology 5.3 Endocrine, Renal, and Gastrointestinal Pathophysiology 5.4 Neurologic, Psychiatric, and Musculoskeletal Pathophysiology 5.5 Physical Assessment and Point-of-Care Testing
6 Chapter 6: Pharmacotherapy & Minor Ailments
6.1 Cardiovascular Pharmacotherapy & Evidence-Based Guidelines 6.2 Endocrine and Metabolic Pharmacotherapy 6.3 Infectious Diseases and Antimicrobial Stewardship 6.4 Neurologic, Psychiatric, and Pain Management Therapeutics 6.5 Minor Ailment Prescribing and Nonprescription Therapy 6.6 Respiratory Pharmacotherapy: Asthma, COPD, and Inhaled Therapy 6.7 Gastrointestinal and Hepatic Pharmacotherapy 6.8 Renal, Fluid, and Electrolyte Therapeutics 6.9 Musculoskeletal and Rheumatologic Pharmacotherapy 6.10 Dermatologic, Ophthalmic, and Ear-Nose-Throat Pharmacotherapy 6.11 Hematologic, Immunologic, and Oncology Supportive Care 6.12 Women's Health, Men's Health, and Urologic Therapeutics 6.13 Nutrition, Natural Health Products, and Complementary Medicine
7 Chapter 7: Special Populations & Applied Therapeutics
7.1 Geriatric Pharmacotherapy and Deprescribing 7.2 Pediatric and Neonatal Pharmacotherapy 7.3 Perinatal Pharmacotherapy: Pregnancy and Lactation 7.4 Dosage Adjustments in Renal and Hepatic Impairment
8 Chapter 8: Prescription Processing, Calculations & Compounding
8.1 Prescription Processing, Verification, and Drug Therapy Problem Management 8.2 Pharmaceutical Calculations and Clinical Math 8.3 Non-Sterile Compounding and NAPRA Standards 8.4 Sterile and Hazardous Compounding under NAPRA Standards 8.5 Advanced Calculations: Infusion Rates, Parenteral Nutrition, and Renal Estimation
9 Chapter 9: Health Equity, Indigenous Health & Pharmacy Bioethics
9.1 Social Determinants of Health and Health Equity 9.2 Indigenous Health, Cultural Safety, and Humility 9.3 Pharmacy Bioethics, Informed Consent, and Professional Boundaries 9.4 Health Promotion, Disease Prevention, and Public Health
10 Chapter 10: Evidence Appraisal, Safety & Practice Management
10.1 Biostatistics and Critical Appraisal of Clinical Literature 10.2 Pharmacoeconomics and Pharmacoepidemiology 10.3 Medication Safety, Incident Analysis, and Quality Improvement 10.4 Pharmacy Operations, Cold-Chain Management, and Emergency Preparedness 10.5 Drug Information and Evidence-Based Decision Making 10.6 Pharmacovigilance and Adverse Drug Reaction Reporting in Canada
11 Chapter 11: Patient Care Process, Communication & Collaborative Practice
11.1 The Patient Care Process: Assessment, Care Plans, and Follow-Up 11.2 Patient and Caregiver Communication, Education, and Health Literacy 11.3 Motivational Interviewing and Shared Decision-Making 11.4 Intra- and Interprofessional Collaborative Care
12 Chapter 12: Medication Administration, Devices & Expanded Scope
12.1 Injection and Vaccine Administration Technique 12.2 Immunization Schedules, Vaccine Selection, and Travel Health 12.3 Home Medical Devices and Device Technique Coaching 12.4 Expanded Scope: Adapting, Renewing, Initiating, and Medication Reconciliation
13 Chapter 13: Pharmacy Management, Finance & Practice Leadership
13.1 Human Resources, Leadership, and Change Management 13.2 Financial Management, Drug Plans, and Marketing 13.3 Quality Improvement, Risk Management, and Workplace Safety
4.2 Cardiovascular, Renal, and Endocrine Pharmacology
Key Takeaways Explain This Topic AI
Inhibition of the renin-angiotensin-aldosterone system with ACE inhibitors, ARBs, or ARNIs reduces cardiovascular and renal morbidity; switching from an ACE inhibitor to sacubitril/valsartan requires a mandatory 36-hour washout to prevent life-threatening angioedema.
Dihydropyridine calcium channel blockers selectively dilate peripheral arterioles, whereas non-dihydropyridines (diltiazem, verapamil) exert negative chronotropic, dromotropic, and inotropic effects and are potent CYP3A4 inhibitors contraindicated in HFrEF.
Loop diuretics (furosemide) block NKCC2 cotransporters in the thick ascending limb, causing calcium and magnesium wasting, whereas thiazides block NCCT cotransporters in the distal convoluted tubule and promote calcium retention.
Diabetes Canada guidelines recommend SGLT2 inhibitors and GLP-1 receptor agonists with proven cardiorenal benefit for patients with type 2 diabetes and atherosclerotic cardiovascular disease, heart failure, or chronic kidney disease.
Thionamide antithyroid therapy requires vigilantly monitoring for agranulocytosis; propylthiouracil (PTU) is preferred in the first trimester of pregnancy and thyroid storm due to peripheral T4-to-T3 conversion blockade, but carries higher fulminant hepatotoxicity risks compared to methimazole.
Last updated: August 2026
4.2 Cardiovascular, Renal, and Endocrine Pharmacology
Cardiovascular, renal, and metabolic disorders represent the highest-volume pharmacotherapeutic encounters in Canadian institutional and community pharmacy practice. Understanding molecular mechanisms, hemodynamic cascades, Canadian clinical practice guidelines (Hypertension Canada, CCS Heart Failure, Diabetes Canada), and toxicities is essential for candidate success on the PEBC Evaluating Examination.
1. Renin-Angiotensin-Aldosterone System (RAAS) and Vasodilator Pharmacology +--------------------------------------------------------------------------------------+
- | RENIN-ANGIOTENSIN-ALDOSTERONE SYSTEM CASCADE |
- +--------------------------------------------------------------------------------------+
- | [Angiotensinogen] (Liver)
- | |
- | v <--- Renin (Juxtaglomerular Cells: stimulated by low perfusion / beta-1)
- | [Angiotensin I]
- | |
- | v <--- ACE / Kininase II (Inhibited by ACE Inhibitors) ===[X] Bradykinin Breakdown
- | [Angiotensin II] (Cough / Angioedema)
- | |
- | +---> AT1 Receptor (Blocked by ARBs) ---> Vasoconstriction + Aldosterone Release
- | +---> AT2 Receptor ---> Vasodilation + Antiproliferation
- | |
- | [Natriuretic Peptides: ANP, BNP] ===> Vasodilation + Natriuresis |
- | |
- | v <--- Neprilysin (Inhibited by Sacubitril) |
- | [Inactive Fragments] |
- +--------------------------------------------------------------------------------------+
- RAAS Inhibitor Classes and Clinical Mechanics
Angiotensin-Converting Enzyme (ACE) Inhibitors (Ramipril, Perindopril, Enalapril) : Inhibit ACE, preventing conversion of Ang I to Ang II, dilating the renal efferent arteriole (reducing intraglomerular pressure and proteinuria), and reducing systemic vascular resistance. Concurrently block kininase II, causing bradykinin accumulation , which mediates dry cough ( 10 − 20 % 10-20\% 10 − 20% ) and rare, life-threatening angioedema .
Angiotensin Receptor Blockers (ARBs: Candesartan, Valsartan, Telmisartan) : Competitive antagonists at the AT 1 \text{AT}_1 AT 1 receptor. Provide equivalent blood pressure lowering and nephroprotection without increasing bradykinin, resulting in minimal cough or angioedema risk.
Angiotensin Receptor-Neprilysin Inhibitors (ARNI: Sacubitril/Valsartan) : Sacubitril prodrug inhibits neprilysin, elevating circulating natriuretic peptides (ANP, BNP, CNP), bradykinin, and adrenomedullin. Valsartan blocks AT 1 \text{AT}_1 AT 1 receptors. Indicated for Heart Failure with Reduced Ejection Fraction (HFrEF, CCS guidelines).
Mandatory Safety Mandate : A 36-hour washout period is legally and clinically required when transitioning a patient from an ACE inhibitor to sacubitril/valsartan. Simultaneous neprilysin and ACE inhibition produces massive bradykinin surges and severe angioedema.
Mineralocorticoid Receptor Antagonists (MRAs) :
Spironolactone : Non-selective MRA; also blocks androgen and progesterone receptors, predisposing to gynecomastia, breast tenderness, and menstrual irregularities.
Eplerenone : Highly selective MRA with minimal endocrine side effects.
Finerenone : Non-steroidal, selective MRA authorized to slow CKD progression and reduce cardiovascular events in type 2 diabetes.
Electrolyte Hazard : All MRAs cause hyperkalemia ; potassium and serum creatinine must be monitored within 1 − 2 weeks 1-2\text{ weeks} 1 − 2 weeks of initiation.
Vasodilators: Calcium Channel Blockers and Nitrates
Drug Class Representative Agents Mechanism of Action Hemodynamic / Clinical Effects Adverse Effects & Pearls
Dihydropyridine CCBs Amlodipine, Nifedipine XL, Felodipine Selective block of vascular L-type Ca 2 + \text{Ca}^{2+} Ca 2 + channels ( Ca v 1.2 \text{Ca}_v1.2 Ca v 1.2 ) Arteriolar vasodilation, ↓ \downarrow ↓ SVR, no intrinsic negative inotropy Peripheral dependent ankle edema (precapillary dilation), reflex tachycardia, flushing, headache
Non-Dihydropyridine CCBs Diltiazem, Verapamil Block L-type Ca 2 + \text{Ca}^{2+} Ca 2 + channels in myocardium, SA node, and AV node Negative chronotropy, negative dromotropy, negative inotropy Bradycardia, AV block, constipation (verapamil relaxes colonic smooth muscle). Potent CYP3A4 and P-gp inhibitors. Contraindicated in HFrEF (LVEF < 40 % <40\% < 40% )
Organic Nitrates Nitroglycerin, Isosorbide dinitrate/mononitrate Bioactivated by mitochondrial ALDH-2 to release NO → ↑ \to \uparrow →↑ cGMP Predominant venodilation → ↓ \to \downarrow →↓ preload, ↓ \downarrow ↓ wall stress; coronary vasodilation Nitrate tolerance avoided via daily 10 − 12 hour 10-12\text{ hour} 10 − 12 hour nitrate-free interval. Co-administration with PDE-5 inhibitors (sildenafil, tadalafil) is strictly contraindicated (fatal refractory hypotension)
2. Renal Pharmacology and Diuretic Mechanisms
Diuretics modulate renal tubular electrolyte transporters, altering sodium excretion, intravascular volume, and systemic hemodynamics. +--------------------------------------------------------------------------------------+
- | RENAL TUBULAR SITES OF DIURETIC ACTION |
- +--------------------------------------------------------------------------------------+
- | 1. Proximal Convoluted Tubule: Carbonic Anhydrase Inhibitors (Acetazolamide) |
- | - Blocks NaHCO3 reabsorption -> alkaline diuresis, metabolic acidosis |
- | 2. Thick Ascending Limb Loop : Loop Diuretics (Furosemide, Bumetanide) |
- | - Blocks NKCC2 cotransporter -> Ca2+ and Mg2+ wasting; abolishes medullary grad |
- | 3. Distal Convoluted Tubule : Thiazides (Hydrochlorothiazide, Chlorthalidone) |
- | - Blocks NCCT cotransporter -> Ca2+ retention; ineffective if eGFR <30 |
- | 4. Cortical Collecting Duct : K+-Sparing Diuretics (Amiloride, Spironolactone) |
- | - Blocks ENaC / Aldosterone -> K+ retention, metabolic acidosis |
- +--------------------------------------------------------------------------------------+
- Diuretic Comparison Matrix
Loop Diuretics (Furosemide, Bumetanide, Torsemide) : Inhibit the luminal Na + / K + / 2 Cl − \text{Na}^+/\text{K}^+/2\text{Cl}^- Na + / K + /2 Cl − (NKCC2) symporter in the thick ascending limb of the loop of Henle. Abolish the hypertonic medullary interstitial gradient, providing potent natriuresis and diuresis. Promote urinary wasting of Na + , K + , Cl − , Mg 2 + \text{Na}^+, \text{K}^+, \text{Cl}^-, \text{Mg}^{2+} Na + , K + , Cl − , Mg 2 + , and Ca 2 + \text{Ca}^{2+} Ca 2 + (used acutely in hypercalcemia). Adverse effects : Hypokalemic metabolic alkalosis, hypocalcemia, hypomagnesemia, hyperuricemia, and ototoxicity (dose-dependent, synergistic with aminoglycosides).
Thiazide and Thiazide-Like Diuretics (Hydrochlorothiazide, Chlorthalidone, Indapamide, Metolazone) : Inhibit the Na + / Cl − \text{Na}^+/\text{Cl}^- Na + / Cl − (NCCT) cotransporter in the distal convoluted tubule. Promote calcium reabsorption via basolateral Na + / Ca 2 + \text{Na}^+/\text{Ca}^{2+} Na + / Ca 2 + exchange (beneficial in osteopenia/osteoporosis and calcium nephrolithiasis). Adverse effects : Hypokalemia, hyponatremia, hypercalcemia, hyperuricemia (precipitating gout), and hyperglycemia. Ineffective as monotherapy when eGFR < 30 mL/min/1.73 m 2 \text{eGFR} < 30\text{ mL/min/1.73 m}^2 eGFR < 30 mL/min/1.73 m 2 (except indapamide and metolazone).
Potassium-Sparing Diuretics (Amiloride, Triamterene) : Directly block Epithelial Sodium Channels (ENaC) in principal cells of the late distal tubule and cortical collecting duct, preventing Na + \text{Na}^+ Na + reabsorption and decreasing the lumen-negative transepithelial potential that drives K + \text{K}^+ K + and H + \text{H}^+ H + secretion.
3. Antiarrhythmic Pharmacology (Vaughan Williams Classification)
Antiarrhythmic drugs modify cardiac ion channels and action potential dynamics: +--------------------------------------------------------------------------------------+
- | VAUGHAN WILLIAMS ANTIARRHYTHMIC CLASSIFICATION |
- +--------------------------------------------------------------------------------------+
- | Class Ia : Moderate Na+ block + K+ block (Procainamide, Quinidine, Disopyramide) |
- | -> Prolongs QRS and APD / QT; intermediate dissociation kinetics |
- | Class Ib : Fast Na+ block (Lidocaine, Mexiletine) |
- | -> Shortens APD; binds ischemic/depolarized tissue; zero QT prolongation |
- | Class Ic : Potent Na+ block (Flecainide, Propafenone) |
- | -> Marked QRS widening, no effect on APD; contraindicated post-MI (CAST) |
- | Class II : Beta-Adrenoceptor Antagonists (Metoprolol, Bisoprolol, Esmolol) |
- | Class III: K+ Channel Blockers (Amiodarone, Dronedarone, Sotalol) |
- | -> Prolongs APD / QT; Torsades de Pointes risk (low with amiodarone) |
- | Class IV : Non-Dihydropyridine CCBs (Verapamil, Diltiazem) |
- | Class V : Adenosine (A1 agonist, converts PSVT), Digoxin, Ivabradine (If blocker) |
- +--------------------------------------------------------------------------------------+
Flecainide and Propafenone (Class Ic) : Exhibit slow dissociation kinetics from open Na + \text{Na}^+ Na + channels. In the Cardiac Arrhythmia Suppression Trial (CAST), Class Ic agents increased mortality in patients with prior myocardial infarction or structural heart disease; they are strictly contraindicated in structural/ischemic heart disease.
Amiodarone (Class III) : Exhibits Class I, II, III, and IV actions. Contains iodine ( 37 % 37\% 37% by weight) and has a prolonged elimination half-life ( t 1 / 2 ≈ 40 − 60 days t_{1/2} \approx 40-60\text{ days} t 1/2 ≈ 40 − 60 days ). Displays low proarrhythmic Torsades de Pointes risk compared to other Class III agents, but carries multisystem toxicities:
Pulmonary Toxicity : Chronic interstitial pneumonitis/fibrosis (requires baseline chest X-ray and pulmonary function tests).
Thyroid Dysfunction : Amiodarone-Induced Hypothyroidism (AIH) or Amiodarone-Induced Thyrotoxicosis (AIT Type 1 vs Type 2; requires baseline and periodic TSH).
Hepatic & Ocular : Elevated AST/ALT, corneal microdeposits (vortex keratopathy), optic neuropathy.
Dermatologic : Photosensitivity and slate blue-gray skin discoloration.
Drug Interactions : Potent inhibitor of CYP3A4, CYP2C9, and P-gp; doubles plasma concentrations of digoxin and warfarin (empirically reduce doses by 50 % 50\% 50% ).
4. Endocrine Pharmacology: Diabetes Mellitus (Diabetes Canada Guidelines) +--------------------------------------------------------------------------------------+
- | DIABETES CANADA TYPE 2 PHARMACOTHERAPY ALGORITHM |
- +--------------------------------------------------------------------------------------+
- | FIRST-LINE: Healthy Behavior Interventions + Metformin (unless contraindicated) |
- | |
- | IF CLINICAL ASCVD, HEART FAILURE, OR CKD PRESENT (Independent of Baseline A1C): |
- | +---> Clinical ASCVD : SGLT2i (Empagliflozin) or GLP-1 RA (Liraglutide, Semaglutide)|
- | +---> Heart Failure : SGLT2i (Dapagliflozin, Empagliflozin with proven HF benefit)|
- | +---> CKD (eGFR/ACR) : SGLT2i (Canagliflozin, Dapagliflozin, Empagliflozin) |
- | |
- | OTHER SECOND-LINE (Glycemic Control Focus): |
- | - DPP-4i (Sitagliptin, Linagliptin) | - GLP-1 RA | - SGLT2i |
- | - Gliclazide (Sulfonylurea) | - Basal Insulin | - Pioglitazone (TZD) |
- +--------------------------------------------------------------------------------------+
- Non-Insulin Antihyperglycemic Agents Matrix
Drug Class Mechanism of Action HbA1c Reduction Weight Effect Hypoglycemia Risk Key Clinical Pearls & Safety Warnings
Biguanides (Metformin) Activates AMPK → ↓ \to \downarrow →↓ hepatic gluconeogenesis, ↑ \uparrow ↑ peripheral glucose uptake 1.0 − 1.5 % 1.0-1.5\% 1.0 − 1.5% Neutral / Mild loss Negligible First-line agent. Contraindicated if eGFR < 30 mL/min/1.73 m 2 \text{eGFR} < 30\text{ mL/min/1.73 m}^2 eGFR < 30 mL/min/1.73 m 2 due to lactic acidosis risk; reduce dose if eGFR < 45 \text{eGFR} < 45 eGFR < 45 . Hold prior to iodinated contrast. Causes vitamin B12 deficiency.
SGLT2 Inhibitors (Empagliflozin, Dapagliflozin, Canagliflozin) Blocks SGLT2 in renal proximal tubule → \to → blocks 90 % 90\% 90% glucose reabsorption → \to → glucosuria 0.5 − 0.8 % 0.5-0.8\% 0.5 − 0.8% Loss ( 2 − 3 kg 2-3\text{ kg} 2 − 3 kg ) Negligible Proven reduction in MACE, CV death, HF hospitalization, and CKD progression. Adverse effects : Mycotic genital infections, volume depletion/orthostasis, euglycemic DKA (euDKA) (hold 3 days 3\text{ days} 3 days prior to elective surgery/acute illness).
GLP-1 Receptor Agonists (Semaglutide, Liraglutide, Dulaglutide) Incretin mimetic: glucose-dependent insulin secretion, ↓ \downarrow ↓ glucagon, delays gastric emptying 1.0 − 1.8 % 1.0-1.8\% 1.0 − 1.8% Significant loss ( 4 − 10 + kg 4-10+\text{ kg} 4 − 10 + kg ) Negligible Proven ASCVD benefit. Contraindications : Personal/family history of Medullary Thyroid Carcinoma (MTC) or MEN-2; history of pancreatitis. Delays oral drug absorption.
DPP-4 Inhibitors (Sitagliptin, Linagliptin, Saxagliptin) Inhibits DPP-4 enzyme, prolonging endogenous active GLP-1 and GIP incretin hormones 0.5 − 0.7 % 0.5-0.7\% 0.5 − 0.7% Neutral Negligible Well tolerated. Linagliptin requires no renal dose adjustment. Saxagliptin carries an increased risk of heart failure hospitalizations. Rare acute pancreatitis.
Sulfonylureas (Gliclazide, Glimepiride, Glyburide) Binds SUR1 on pancreatic β \beta β -cell K ATP K_{\text{ATP}} K ATP channels → \to → channel closure → \to → depolarization → ↑ \to \uparrow →↑ insulin exocytosis 0.8 − 1.2 % 0.8-1.2\% 0.8 − 1.2% Gain High Gliclazide preferred over glyburide. Glyburide has active metabolites that accumulate in renal impairment, causing severe prolonged hypoglycemia.
Thiazolidinediones (Pioglitazone, Rosiglitazone) PPAR- γ \gamma γ nuclear receptor agonist → ↑ \to \uparrow →↑ insulin sensitivity in muscle/adipose 0.8 − 1.2 % 0.8-1.2\% 0.8 − 1.2% Gain Negligible Fluid retention and peripheral edema; contraindicated in NYHA Class III/IV Heart Failure . Increased fracture risk in females; bladder cancer warning (pioglitazone).
Insulin Formulations and Pharmacokinetics Ultra-Rapid / Rapid (Aspart, Lispro, Glulisine) : Onset 10 − 15 min , Peak 1 − 2 h , Duration 3 − 5 h (Bolus / Prandial) Short-Acting Regular (Humulin R, Novolin Toronto) : Onset 30 − 60 min , Peak 2 − 4 h , Duration 6 − 8 h (IV Infusions in DKA) Intermediate (NPH) : Onset 1 − 3 h , Peak 4 − 8 h , Duration 12 − 18 h (Turbid suspension) Long-Acting Basal (Glargine U100/U300, Detemir, Degludec) : Onset 1 − 2 h , Peakless , Duration 24 − 42 + h (Degludec t 1 / 2 ≈ 25 h) \begin{aligned}
\textbf{Ultra-Rapid / Rapid (Aspart, Lispro, Glulisine)} &: \text{Onset } 10-15\text{ min}, \text{Peak } 1-2\text{ h}, \text{Duration } 3-5\text{ h (Bolus / Prandial)} \\
\textbf{Short-Acting Regular (Humulin R, Novolin Toronto)} &: \text{Onset } 30-60\text{ min}, \text{Peak } 2-4\text{ h}, \text{Duration } 6-8\text{ h (IV Infusions in DKA)} \\
\textbf{Intermediate (NPH)} &: \text{Onset } 1-3\text{ h}, \text{Peak } 4-8\text{ h}, \text{Duration } 12-18\text{ h (Turbid suspension)} \\
\textbf{Long-Acting Basal (Glargine U100/U300, Detemir, Degludec)} &: \text{Onset } 1-2\text{ h}, \text{Peakless}, \text{Duration } 24-42+\text{ h (Degludec } t_{1/2} \approx 25\text{ h)}
\end{aligned} Ultra-Rapid / Rapid (Aspart, Lispro, Glulisine) Short-Acting Regular (Humulin R, Novolin Toronto) Intermediate (NPH) Long-Acting Basal (Glargine U100/U300, Detemir, Degludec) : Onset 10 − 15 min , Peak 1 − 2 h , Duration 3 − 5 h (Bolus / Prandial) : Onset 30 − 60 min , Peak 2 − 4 h , Duration 6 − 8 h (IV Infusions in DKA) : Onset 1 − 3 h , Peak 4 − 8 h , Duration 12 − 18 h (Turbid suspension) : Onset 1 − 2 h , Peakless , Duration 24 − 42 + h (Degludec t 1/2 ≈ 25 h)
- 5. Thyroid and Adrenal Pharmacotherapy
- Thyroid Pharmacotherapy: Hypothyroidism and Thyrotoxicosis
Levothyroxine ( T 4 T_4 T 4 ) : Synthetic thyroxine, converted peripherally to active triiodothyronine ( T 3 T_3 T 3 ) by 5 ′ 5' 5 ′ -deiodinase. Half-life is 7 days 7\text{ days} 7 days ; steady-state requires 6 − 8 weeks 6-8\text{ weeks} 6 − 8 weeks . Narrow therapeutic index drug. Take once daily in the morning on an empty stomach with a full glass of water, ≥ 30 − 60 minutes \ge 30-60\text{ minutes} ≥ 30 − 60 minutes before breakfast. Avoid co-administration within 4 hours 4\text{ hours} 4 hours of calcium, iron, magnesium, or bile acid sequestrants.
Thionamides (Methimazole vs. Propylthiouracil [PTU]) :
Inhibit thyroid peroxidase (TPO), blocking iodine organification and iodotyrosine coupling.
Propylthiouracil (PTU) also inhibits peripheral 5 ′ 5' 5 ′ -deiodinase conversion of T 4 → T 3 T_4 \to T_3 T 4 → T 3 .
Methimazole is first-line due to once-daily dosing and lower hepatotoxicity.
PTU Indications : Preferred during the first trimester of pregnancy (methimazole causes embryopathy: aplasia cutis, choanal atresia) and in thyroid storm (due to peripheral T 4 → T 3 T_4 \to T_3 T 4 → T 3 inhibition). PTU carries a black-box warning for fulminant hepatic failure .
Agranulocytosis : Rare ( 0.2 − 0.5 % 0.2-0.5\% 0.2 − 0.5% ) life-threatening complication of both thionamides. Patients presenting with fever, chills, or sore throat must stop the drug immediately and obtain an urgent CBC with differential.